IBO - Rasio utang marang kapitalisasi buku Impact BioMedical Inc

The distribution of debt capital within the balance sheet capitalization on this GURU.Markets chart demonstrates a liquidity deficit for Impact BioMedical Inc (IBO) due to a lack of sales and early-stage research. The value 0.00 characterizes this valuation parameter, which is further complicated by logistics disruptions and sanction barriers for exports. The risks of resource fragmentation across various niches and the need for investment threaten the holding's margins.

Impact BioMedical, Inc. - Utang-utang marang kapitalisasi buku IBO (periode 17.09.2024 - 27.10.2026)

Impact BioMedical Inc (IBO) focuses on biomedical research while maintaining a minimal environmental footprint. This metric compares total liabilities to net assets, determining the extent to which equity covers debt. A decrease in this value indicates financial stability, while an increase signals bankruptcy risk. By analyzing the debt-to-book capitalization ratio of Impact BioMedical Inc (IBO), investors can gauge the real-time market reaction. This chart reflects the balance between debt-funded expansion and solvency.

Pesaing Impact BioMedical Inc

Rasio utang marang kapitalisasi buku Haleon plc|kenvue.com - Rasio utang marang aset resik|VRNA: Rasio utang marang kapitalisasi buku|MENS - Utang marang nilai buku|LGND: Utang-utang marang kapitalisasi buku|Utang-utang marang kapitalisasi buku Amneal Corp|PRGO - Utang marang nilai buku|Rasio utang marang aset resik ALVO|Liquidia - Rasio utang marang kapitalisasi buku|Utang-utang marang nilai buku Galapagos N.V. GLPG|Utang marang nilai buku ANI Pharma (ANIP)|Utang marang modal buku Afrezza MNKD|Utang-utang marang kapitalisasi buku Amphastar Pharmaceuticals (AMPH)|PCRX - Rasio utang marang aset resik|Utang-utang marang kapitalisasi buku SPRY|TBPH (Theravance Biopharma Inc) - Utang-utang marang nilai buku|AQST - Rasio utang marang kapitalisasi buku|Rasio utang marang aset resik scPharma|TECX (Tectonic Therapeutic, Inc.) - Utang-utang marang kapitalisasi buku|Utang-utang marang aset resik TNXP (tonixpharma.com)|China SXT Pharmaceuticals, Inc. - Rasio utang marang kapitalisasi buku|Eupraxia Pharmaceuticals, Inc. - Utang marang nilai buku|Rasio utang marang kapitalisasi buku BioHarvest|EXOZ - Rasio utang-utang marang kapitalisasi buku|ORMP: Utang-utang marang kapitalisasi buku|Entera Bio (ENTX) - Utang-utang marang kapitalisasi buku|Utang-utang marang kapitalisasi buku HYFT|Utang marang nilai buku ABVC BioPharma Inc. (ABVC)|Utang marang nilai buku Cumberland Pharma|Utang marang modal buku Quantum BioPharma Corp QNTM|Utang marang nilai buku FibroGen, Inc.|Rasio utang marang aset resik telomirpharma.com TELO|RANI - Utang-utang marang kapitalisasi buku|SNYR - Rasio utang marang kapitalisasi buku|rallybio.com - Utang-utang marang kapitalisasi buku|LEXX (Lexaria Bioscience Corp.) - Utang-utang marang aset resik|Rasio utang marang kapitalisasi buku PULM (Pulmatrix, Inc.)|Utang-utang marang nilai buku PTHL|Rasio utang marang kapitalisasi buku APM (Aptorum Group Limited)|Utang marang nilai buku Lyra Therapeutics Inc. (LYRA)|TNFA: Utang-utang marang kapitalisasi buku|Utang-utang marang nilai buku cbdMD Inc. YCBD|PainReform Ltd. (PRFX) - Utang-utang marang kapitalisasi buku|CYTO - Rasio utang marang nilai buku|Lipella Pharmaceuticals, Inc. - Utang-utang marang kapitalisasi buku|OptiNose Inc (OPTN) - Utang-utang marang aset resik|Utang-utang marang kapitalisasi buku PIRS|Utang marang nilai buku Procaps Group Corp|Utang-utang marang kapitalisasi buku PTPI|Utang-utang marang kapitalisasi buku QLI (qlsyy.net)|Rasio utang marang kapitalisasi buku ACELYRIN SLRN|TFFP - Rasio utang marang kapitalisasi buku